Clinical Trial Update: Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients [Phase 2]

View source ↗

Summary

Ongoing Phase 2 neoadjuvant trial evaluating cemiplimab for resectable non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Libtayo (cemiplimab) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Non-small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING